BIIB logo

Biogen Inc. (BIIB)$193.76

Market Cap: 17.85 BCurrency: USD

Research Snapshot

Static fundamentals, valuation context, and investor signals for Biogen Inc. (BIIB).

HEALTHCARE
DRUG MANUFACTURERS - GENERAL
DCF ready

Valuation

10.3x

EV/FCF, 9.7% FCF yield

Quality

5.3%

ROIC, 20.7% FCF margin

Growth

-6.0%

5Y sales (revenue) CAGR

Balance sheet

0.3x

Debt/equity, 2.7x current ratio

Superinvestors

2

Top: Hillman Value Fund (3.8%)

Strengths to research

  • Free cash flow margin is healthy at 20.7%.
  • Debt/equity looks manageable at 0.3x.
  • 10 annual periods are available for trend analysis.

Watchouts

  • Five-year revenue trend is negative at -6.0%.
Annual data: 10 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026

Quality Scorecard

Build-time composite score for BIIB.

Grade F
23
/ 100

Peer Comparison

Target stock against 8 market-cap comparable peers.

Heat map: red worst to green best
BIIB
Target
Biogen Inc.$17.8B22.0x10.3x5.3%-6.0%20.7%N/AN/AN/A
BAYRYBayer Ag Sponsored ADR$26.9BN/AN/AN/AN/AN/AN/AN/AN/A
GSKGSK plc$79.0BN/AN/AN/AN/AN/AN/AN/AN/A
BMYBristol-Myers Squibb$101.9B17.2x10.6x11.1%2.5%26.7%N/AN/AN/A
GILDGilead Sciences$128.0B19.8x15.4x17.9%3.6%32.1%N/A1.7xN/A
SNYSanofi Aventis$133.3BN/AN/AN/AN/AN/AN/AN/AN/A
PFEPfizer Inc.$135.4B19.0x14.8x9.0%8.5%14.5%N/AN/AN/A
OGNOrganon & Co.$2.3B18.7x19.2x2.0%-1.0%8.7%53.3%N/AN/A
AMGNAmgen$150.6B23.8x24.2x12.2%7.6%22.0%N/A3.2xN/A

Financial Charts

No financial data available for BIIB (annual).

2 superinvestors own BIIB

Current quarter ownership and quarter-over-quarter share changes.

Superinvestor ownership
FundSharesValue% PortfolioQoQ Change
Samantha McLemore

Patient Capital Management

379,741$70M2.60%0.0%
Hillman Value Fund

Hillman Value Fund

29,540$5M3.76%0.0%